"Some Hope": Biogen, Eisai Release Positive Phase II Results for Alzheimer's Candidate

Seven months after disclosing disappointing initial results from a Phase II trial of BAN2401, Biogen and Eisai this week released a more positive topline “final analysis” showing that their Alzheimer’s disease candidate achieved a statistically significant slowing of clinical decline and reduction of amyloid beta accumulated in the brain.The Phase II trial, Study 201 ( NCT01767311 ), achieved statistically significance on two key endpoints, the companies said.One was a slowdown